Michael Nova, M.D.
Chief Innovation Officer
Dr. Nova is currently the chief innovation officer of Pathway Genomics, and was a founding team member of the company. He is the inventor of the Pathway/IBM Watson big data/deep learning mobile application (OME™), and also the entire wellness (PathwayFit®, SkinFit® and Healthy Weight DNA Insight®), cardiac, and mental health line of genetic testing products. For Pathway, Dr. Nova has also executed major corporate alliances with Fortune 500 companies.
His scientific career began as a research associate at the Salk Institute in the laboratory of Nobel Laureate Roger Guillemin, where he studied the genetics and proteomics of human growth factors and cancers. Dr. Nova was the founder and CEO of Discovery Partners Inc. (Nasdaq: DPII), which completed a successful $150M IPO and marketed wireless drug discovery technology and radio-frequency combinatorial chemistry to large pharmaceutical companies. Intellectual property developed by Dr. Nova at DPII included the original “barcode on bead patents” used by many diagnostic and DNA companies. He then founded the wireless sensory network company Graviton, where he was responsible for raising $60 million in capital from venture groups such as Kleiner Perkins, InQtel and large corporations such as Motorola and Qualcomm. Dr. Nova is also a 2005 World Economic Forum Technology Pioneer Award Winner, and the physician of record on the first person ever to have their entire genome sequenced by Illumina (2009). He is also on the Board of Advisors for IBM Watson, Metagenics and The Salk Institute.
Dr. Nova has over 30 issued, and 35 pending, patents and has numerous publications in peer-reviewed journals. With degrees in biochemistry, physics, and medicine, Dr. Nova is a Board-certified dermatopathologist licensed in California. In his minimal spare time, Michael likes to surf big waves in Indonesia and Mexico, and he also helped build a WHO-sanctioned basic care clinic in the Fijian town of Nabila.